Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00089
|
|||||
| Drug Name |
Gabapentin enacarbil
|
|||||
| Synonyms |
ASP8825; GSK 1838262; Gabapentin-XP; Horizant; Regnite; Solzira; XP13512
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Postherpetic neuralgia [ICD11: 1E91.5] | Approved | [1] | |||
| Therapeutic Class |
Neurology Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H27NO6
|
|||||
| Canonical SMILES |
CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
|
|||||
| InChI |
InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)
|
|||||
| InChIKey |
TZDUHAJSIBHXDL-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 478296-72-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 329.39 | Topological Polar Surface Area | 102 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:68840
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MCT1 | Transporter Info | Monocarboxylate transporter 1 | Substrate | [2] | |
| SMCT1 | Transporter Info | Sodium-coupled monocarboxylate transporter 1 | Substrate | [3] | ||
| SMVT | Transporter Info | Sodium-dependent multivitamin transporter | Substrate | [3] | ||
| References | ||||||
| 1 | Gabapentin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21. | |||||
| 3 | Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.